Mesoblast: Achieves ASX 200 listing
- Mesoblast is now joining the big players in the Australian Securities Exchange (ASX)
- The ASX 200 comprised of 200 of the largest companies on the ASX and helps measure Australia’s equity performance
- Before COVID-19, Mesoblast (MSB) started the year off at $3 per share on January 27
- However, the company shot up towards the end of March and ended today on $3.60 per share
- One of the reasons for the increase could be the announcement of MSB’s coronavirus research
- Mesoblast believes it is in a strong financial position to enter the 2021 financial year
